Company Profiles

driven by the PitchBook Platform

Thetis Pharmaceuticals

Description

Developer of pharmaceutical drugs. The company is focused on type 2 diabetes, and is working to advance its TP101, which is a new molecular entity that chemically combines metformin, the standard of care in type 2 diabetes, with the principal component from omega-3 polyunsaturated fatty acids. Its TP101 uniquely targets both glycemic and lipid control in diabetes patients and has the potential to address cardiovascular complications.

2011

Founded

PRIVATE

Status

Early Stage VC

Latest Deal Type

$4.11M

Latest Deal Amount

$12.4M

Total Amount Raised

6

Investors

Description

Developer of pharmaceutical drugs. The company is focused on type 2 diabetes, and is working to advance its TP101, which is a new molecular entity that chemically combines metformin, the standard of care in type 2 diabetes, with the principal component from omega-3 polyunsaturated fatty acids. Its TP101 uniquely targets both glycemic and lipid control in diabetes patients and has the potential to address cardiovascular complications.

Website:

www.thetispharma.com

Ownership Status

Privately held (backing)

Financing Status

Venture Capital-Backed

Primary Industry

Drug Discovery

Other Industries

Pharmaceuticals
Drug Delivery

Primary Office

167 Old Post Road 2nd Floor Fairfield, CT 06890United States +1 (860) 213-1235
Request a free trial to the PitchBook Platform
You're viewing a free company profile from the PitchBook Platform. To explore Thetis Pharmaceuticals's full profile, request a free trial.

Thetis Pharmaceuticals Valuation and Funding

Request access
Deal TypeDateAmountRaised to DatePost-ValStatusStage

Thetis Pharmaceuticals Investors (6)

Request access
Investor NameInvestor TypeHoldingInvestor SinceParticipating RoundsBoard
Seat
Contact
Info
Connecticut InnovationsVenture CapitalMinority000 0000000 0000
Individual InvestorAngel (individual)Minority000 0000000 0000
Paul SilvaAngel (individual)Minority000 0000000 0000
River Valley InvestorsAngel GroupMinority000 0000000 0000
Stonehenge Capital CompanyPE/BuyoutMinority000 0000000 0000
Connecticut Innovations Venture Capital
Individual Investor Angel (individual)
Paul Silva Angel (individual)
River Valley Investors Angel Group
Stonehenge Capital Company PE/Buyout

Thetis Pharmaceuticals Executive Team (3)

NameTitleBoard
Seat
Contact
Info
Frank Sciavolino Ph.DCo-Founder, President, Chief Scientific Officer and Board Member
Gary MathiasCo-Founder, Chief Executive Officer, Chief Revenue Officer, Manager & Board Member
Alexander Fleming MDChief Clinical and Regulatory Officer
Frank Sciavolino Ph.D Co-Founder, President, Chief Scientific Officer and Board Member
Gary Mathias Co-Founder, Chief Executive Officer, Chief Revenue Officer, Manager & Board Member
Alexander Fleming MD Chief Clinical and Regulatory Officer

Thetis Pharmaceuticals Board Members (5)

NameRepresentingRoleSinceContact
Info
David WurzerConnecticut InnovationsExecutive Vice President & Chief Investment Officer000 0000
Dennis WillsonSelfBoard Member000 0000
Frank Sciavolino Ph.DThetis PharmaceuticalsCo-Founder, President, Chief Scientific Officer and Board Member000 0000
Gary MathiasSelfCo-Founder, Chief Executive Officer, Chief Revenue Officer, Manager & Board Member000 0000
Lillian MuConnecticut InnovationsSenior Investment Associate000 0000
David Wurzer Executive Vice President & Chief Investment Officer Connecticut Innovations
Dennis Willson Board Member Self
Frank Sciavolino Ph.D Co-Founder, President, Chief Scientific Officer and Board Member Thetis Pharmaceuticals
Gary Mathias Co-Founder, Chief Executive Officer, Chief Revenue Officer, Manager & Board Member Self
Lillian Mu Senior Investment Associate Connecticut Innovations
Request full access to PitchBook